chondrosarcoma/diarrea

Il collegamento viene salvato negli appunti

ArticoliTest cliniciBrevetti

Scegli il tipo di ordinamento

9 risultati

Anticancer effects of adriamycin-loaded hydroxyapatite implants determined in a Swarm rat chondrosarcoma model.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

We investigated the antitumor effects of adriamycin (ADR)-loaded hydroxyapatite (HAP) beads in a Swarm rat chondrosarcoma model. When one ADR-loaded HAP bead (ADR: 0.8 mg/bead) was implanted into the central portion of a rat bearing tumor, the ADR-loaded HAP beads showed good therapeutic effects,

Extraskeletal myxoid chondrosarcoma with massive pulmonary metastases.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

Extraskeletal myxoid chondrosarcoma (EMC) is a rare malignant mesenchymal neoplasm of uncertain differentiation characterized by rearrangements of the NR4A3 gene. EMC often affects adults around the age of 50 and arise in the deep tissues of the proximal extremities and limb girdles.

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

N-Phosphonacetyl-L-aspartic acid (PALA) is new synthetic antimetabolite which inhibits de novo pyrimidine biosynthesis. Its significant activity against Lewis lung carcinoma, B16 melanoma, and glioma 26 suggested that it might be useful in the treatment of human solid tumors. Phase I trials revealed

Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

Thirty-seven patients with inoperable malignancies were given 75 courses of N-(phosphonaceteyl)-L-aspartic acid (PALA). Twenty-seven of these patients received PALA as a continuous iv infusion over 24 hours at dose levels ranging from 500 to 10,500 mg/m2 of estimated body surface area. In addition,

Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

OBJECTIVE LY293111, a novel diaryl ether carboxylic acid derivative, is a potent and selective inhibitor of the lipoxygenase pathway either directly through 5'-lipoxygenase or via antagonism of the leukotriene B4 (LTB4) receptor. More recently it has been determined to have peroxisome proliferator

Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

To evaluate the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS, DoceAqualip) based chemotherapy in patients with sarcoma.

Methods

In this retrospective, multicenter (6 centers), observational study, we analyzed the medical charts of

Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

OBJECTIVE MAC-321 is a novel taxane that has demonstrated exceptional activity in human xenograft models when administered intravenously and orally. Preclinical studies of MAC-321 have shown antitumor activity in MDR-expressing and paclitaxel-resistant tumors. This phase I dose escalation study was

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

Trabectedin (ET743, Yondelis(®), manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine ascidian, Ecteinascidia turbinata, is a natural alkaloid with multiple complex mechanisms of action. On 23 October 2015, 15 years after the

Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

Twenty previously treated patients with advanced bone sarcomas received thrice weekly im 50 X 10(6) IU/m2 doses of human alfa-interferon (interferon alfa-2a, recombinant; Roche). Seventeen patients had metastatic osteosarcomas and one each had fibrosarcoma, mesenchymal chondrosarcoma, and malignant

Unisciti alla nostra
pagina facebook

Herbal & Natural Medicine

Il database di erbe medicinali più completo supportato dalla scienza

Funziona in 55 lingue
Cure a base di erbe sostenute dalla scienza
Riconoscimento delle erbe per immagine
Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
Leggi le pubblicazioni scientifiche relative alla tua ricerca
Cerca le erbe medicinali in base ai loro effetti
Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti

Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate